Imricor Receives FDA Pediatric Clearances for iMR Device
Open PDF
| Stock | Imricor Medical Systems Inc (IMR.ASX) |
|---|---|
| Release Time | 2 Jul 2026, 8:33 a.m. |
| Price Sensitive | Yes |
This feature provides summaries of price-sensitive announcements for companies followed by users on InvestorPA.
The summaries are generated by large language models so please interpret with care.
Imricor Receives FDA Pediatric Clearances for iMR Device
Key Points
- Imricor received FDA 510(k) clearance for NorthStar's pediatric use
- FDA cleared Vision-MR Diagnostic Catheter for pediatric use
- Clearances target pediatric patients sensitive to radiation exposure
- Pediatric market seen as an early commercial channel
- CEO highlights the importance of radiation-free procedures for children
Full Summary
Imricor Medical Systems, Inc. (ASX: IMR) announced it has received 510(k) clearance from the U.S. Food and Drug Administration (FDA) for its NorthStar system and Vision-MR Diagnostic Catheter for pediatric label expansion. This clearance allows Imricor to market these devices for use with patients of any age, including children. The pediatric market represents an attractive early commercial channel for Imricor's products, particularly for children's hospitals interested in reducing radiation exposure and the use of contrast dyes. Imricor's Chair and CEO, Steve Wedan, emphasized the company's commitment to providing technology that benefits all patient segments, particularly infants and young children.
Sign in to get more information about the company, including guidance changes and other insights.
Sign In